Replies to post #145084 on Biotech Values

[mcbio]

a vaccine provides immunity for a long time and could be added to one of the other standard vaccines:

Ok thanks. As genisi posted before (#msg-67654286 ), AZN/Medimmune is the key competition in the RSV vaccine space and you would think that if anyone would be able to turn Synagis into an effective vaccine, it would be Synagis' inventor. We should check in on Medimmune's RSV vaccine candidates, MEDI-559 and MEDI-534, to see if they have reported efficacy data yet. These are just a bit ahead of NVAX's RSV vaccine it would appear. That said, it's a very large market and I assume there would be room for several players; think a big key would be to what extent, if any, NVAX's RSV vaccine is differentiated from Medimmune's candidates. As noted in item 2 of #msg-76657417, NVAX generated Synagis antibodies 10-fold higher than what Medimmmune calculated was the protective level of antibodies for Synagis. I wonder how this compares to Medimmune's RSV vaccine candidates.